Explanatory Notes

Segment Reporting

As of March 31, 2018, the Bayer Group comprises the four reportable segments Pharmaceuticals, Consumer Health, Crop Science and Animal Health.

The following table shows the reconciliation of EBITDA before special items of the above-mentioned segments and the reconciliation to income before income taxes of the Group from continuing operations:

Reconciliation of Segments’ EBITDA Before Special Items to Group Income Before Income Taxes

 

 

Q1 2017

 

Q1 2018

 

 

€ million

 

€ million

2017 figures restated

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

EBITDA before special items of segments

 

3,189

 

2,996

EBITDA before special items of Corporate Functions and Consolidation

 

(135)

 

(100)

EBITDA before special items1

 

3,054

 

2,896

Depreciation, amortization and impairment losses before special items of segments

 

(522)

 

(504)

Depreciation, amortization and impairment losses before special items of Corporate Functions and Consolidation

 

(3)

 

(4)

Depreciation, amortization and impairment losses before special items

 

(525)

 

(508)

EBIT before special items of segments

 

2,667

 

2,492

EBIT before special items of Corporate Functions and Consolidation

 

(138)

 

(104)

EBIT before special items1

 

2,529

 

2,388

Special items of segments

 

(100)

 

(75)

Special items of Corporate Functions and Consolidation

 

(2)

 

(3)

Special items1

 

(102)

 

(78)

EBIT of segments

 

2,567

 

2,417

EBIT of Corporate Functions and Consolidation

 

(140)

 

(107)

EBIT1

 

2,427

 

2,310

Financial result

 

(296)

 

130

Income before income taxes

 

2,131

 

2,440

Compare to Last Year